Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Learning to rectify my personal and professional identities has not always been easy, but finally getting to a place where the two can work together has led me to the most fulfilling portion of my career in urology.
Health-care inequality exists in marginalized groups such as the LGBT+ community. Having been involved in setting up a urological service to connect with this community, I reflect on how health-care organizations must prioritize the unmet needs of this group in order to strive for equality.
The BJU International paper by van de Grift and colleagues includes important data outlining the long-term cosmetic and functional outcomes for masculinizing surgery in patients born with differences in sex development. This overview highlights some of the important findings and their context in what can be a controversial subject.
In this Review, the authors discuss how machine learning can improve sperm selection, focusing on the near-term, achievable machine learning methods based on available assessments of selected sperm and the areas in which the most considerable gains are possible.
The formation of kidney stones is governed by the same principles as other stone systems. These ‘diagenetic phase transitions’ that create human kidney stones reflect the environment within the kidney during stone formation and could, therefore, improve understanding of urolithiasis and enable future treatment development. In this wide-ranging and unique Review, the authors explain how kidney stone formation parallels that of other stone systems such as stony corals, travertine in Roman aqueducts, stalactites and agates, and describe how the new field of GeoBioMed could be harnessed to improve patient care.
Non-metastatic CRPC (nmCRPC) is a heterogeneous, man-made disease stage that has received increased attention. Historically, few options were available to treat nmCRPC; however, three novel nonsteroidal antiandrogens, enzalutamide, apalutamide and darolutamide, are now available for men with this disease.
